Cynthia Sirard - Leap Therapeutics Chief Officer
| LPTX Stock | USD 2.52 0.03 1.18% |
Insider
Cynthia Sirard is Chief Officer of Leap Therapeutics
| Age | 54 |
| Address | 47 Thorndike Street, Cambridge, MA, United States, 02141 |
| Phone | 617 714 0360 |
| Web | https://www.leaptx.com |
Cynthia Sirard Latest Insider Activity
Tracking and analyzing the buying and selling activities of Cynthia Sirard against Leap Therapeutics stock is an integral part of due diligence when investing in Leap Therapeutics. Cynthia Sirard insider activity provides valuable insight into whether Leap Therapeutics is net buyers or sellers over its current business cycle. Note, Leap Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Leap Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Cynthia Sirard over two months ago Acquisition by Cynthia Sirard of 5000 shares of Leap Therapeutics subject to Rule 16b-3 |
Leap Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4562) % which means that it has lost $0.4562 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8054) %, meaning that it created substantial loss on money invested by shareholders. Leap Therapeutics' management efficiency ratios could be used to measure how well Leap Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.17 in 2024. Return On Capital Employed is likely to rise to -1.37 in 2024. At this time, Leap Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.3 M in 2024, whereas Total Assets are likely to drop slightly above 45.2 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Joseph Ferra | Elevation Oncology | 49 | |
| MBBS MD | Mereo BioPharma Group | 54 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| MSc MBA | Inozyme Pharma | 52 | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| John Lewicki | Mereo BioPharma Group | 72 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| MBA MBA | Inozyme Pharma | 65 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.46 |
Leap Therapeutics Leadership Team
Elected by the shareholders, the Leap Therapeutics' board of directors comprises two types of representatives: Leap Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Leap. The board's role is to monitor Leap Therapeutics' management team and ensure that shareholders' interests are well served. Leap Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Leap Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Augustine Lawlor, Chief Officer | ||
| Cynthia MD, Chief Officer | ||
| Christine Granfield, VP Quality | ||
| Mark OMahony, Chief Officer | ||
| Jason Baum, Chief Officer | ||
| Douglas JD, General CFO | ||
| Cynthia Sirard, Chief Officer | ||
| Walter Newman, Research Fellow |
Leap Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Leap Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 34.11 M | ||||
| Shares Outstanding | 38.32 M | ||||
| Shares Owned By Insiders | 17.28 % | ||||
| Shares Owned By Institutions | 40.30 % | ||||
| Number Of Shares Shorted | 1.01 M | ||||
| Price To Earning | (1.85) X | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 160.10 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.